Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2025 - 2030

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 16.55 billion by 2030, registering a CAGR of 10.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights

• Based on condition, the market includes myeloma, lymphoma, breast cancer and others. The myeloma segment led the market with the largest revenue share of 49.61% in 2024. The lymphoma segment is anticipated to witness the fastest CAGR during the forecast period.
• Based on linker, the market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linkers segment led the market with the largest revenue share of 56.1% in 2024.
• The antibody drug conjugates contract manufacturing market in North America is expected to witness the fastest CAGR over the forecast period.
• Asia Pacific antibody drug conjugates contract manufacturing market dominated the market with the largest revenue share of 40.93% in 2024. The regional growth is primarily owing to supportive regulatory reforms, especially in countries such as India & China, and low-cost labor.